BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25430636)

  • 1. Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel 8-Color Flow Cytometry Approach.
    Chovancová J; Bernard T; Stehlíková O; Sálek D; Janíková A; Mayer J; Doubek M
    Cytometry B Clin Cytom; 2014 Nov; ():. PubMed ID: 25430636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.
    Chovancová J; Bernard T; Stehlíková O; Šálek D; Janíková A; Mayer J; Doubek M
    Cytometry B Clin Cytom; 2015 Mar; 88(2):92-100. PubMed ID: 25586981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
    Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Flow Cytometry Panel for Differential Diagnosis of Mantle Cell Lymphoma from Atypical B-Chronic Lymphocytic Leukaemia.
    Mehrpouri M; Sadat Hosseini M; Jafari L; Mosleh M; Shahabi Satlsar E
    Iran Biomed J; 2023 Jan; 27(1):15-22. PubMed ID: 36624655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Denys B; van der Sluijs-Gelling AJ; Homburg C; van der Schoot CE; de Haas V; Philippé J; Pieters R; van Dongen JJ; van der Velden VH
    Leukemia; 2013 Mar; 27(3):635-41. PubMed ID: 22945774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
    Cheminant M; Derrieux C; Touzart A; Schmit S; Grenier A; Trinquand A; Delfau-Larue MH; Lhermitte L; Thieblemont C; Ribrag V; Cheze S; Sanhes L; Jardin F; Lefrère F; Delarue R; Hoster E; Dreyling M; Asnafi V; Hermine O; Macintyre E
    Haematologica; 2016 Mar; 101(3):336-45. PubMed ID: 26703963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
    Wasik AM; Priebe V; Lord M; Jeppsson-Ahlberg Å; Christensson B; Sander B
    Leuk Lymphoma; 2015 May; 56(5):1425-31. PubMed ID: 25120048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
    Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
    Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia.
    Hrabovsky S; Folber F; Horacek JM; Stehlikova O; Jelinkova H; Salek C; Doubek M;
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):743-748. PubMed ID: 30057330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.
    Qiu L; Xu J; Tang G; Wang SA; Lin P; Ok CY; Garces S; Yin CC; Khanlari M; Vega F; Medeiros LJ; Li S
    Hum Pathol; 2022 Jan; 119():59-68. PubMed ID: 34767860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.
    Andersen NS; Donovan JW; Borus JS; Poor CM; Neuberg D; Aster JC; Nadler LM; Freedman AS; Gribben JG
    Blood; 1997 Nov; 90(10):4212-21. PubMed ID: 9354694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
    Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
    Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders].
    Yi S; Li Z; Wang H; Liu W; Lyu R; Yu Z; Qi J; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):337-41. PubMed ID: 24759024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric MRD detection in selected mature B-cell malignancies.
    Böttcher S; Ritgen M; Kneba M
    Methods Mol Biol; 2013; 971():149-74. PubMed ID: 23296963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.